Best EU Biotech Podcasts (2025)

1
New GMOs deregulated: The wet dream of the biotech industry coming true 27:11

17d ago27:11

27:11

Listen to our new podcast episode, where Nina Holland talks about the intense lobby battle that the biotech industry has been waging to get its new generation of genetic modification techniques excluded from European GMO regulations. GMO stands for genetically modified organisms. This will mean that crops or wild plants made by using this new gener…

1
Shipping Goes Net Zero, Sell America and Talking Circular Economy 42:01

2d ago42:01

42:01

Description: In Episode 79 of Trade Splaining, Rob and Ardian dive deep into the surprising relevance of decarbonizing global shipping, why GDP might not be the best metric anymore, and how the EU and UK are slowly making Brexit... not a thing. We also ask: is multilateralism really dead—or just resting? 💡 What You'll Hear in This Episode: Circular…

1
Chris Martin, Verona Pharma 🇬🇧 | Ohtuvayre, COPD, Execution | E34 55:24

6d ago55:24

55:24

We’re online with Chris Martin, COO of the 6th most valuable biotech in Europe, Verona Pharma. Their amazing story sees them bring a fully-owned respiratory drug to market and multiply its valuation by 120x within the last 5 years (from $50M to $6B today) 💸We talk about the commercial rollout of Ohtuvayre, Verona’s drug. We also discuss the British…

1
Jenni Nordborg: Life Sciences Governance & EU Regulatory Alignment 25:45

10d ago25:45

25:45

In this episode of the Vital Health Podcast, host Duane Schulthess sits down with Jenni Nordborg, Director of International Affairs at The Swedish Association of the Pharmaceutical Industry (LIF), to explore how national and European policies intersect to shape life sciences innovation. They discuss Sweden’s holistic governance model, the strategic…

1
Education, innovation, and the AI Leap 51:44

12d ago51:44

51:44

We explore Estonia’s bold leap into AI-powered education with insights from Gert Jervan, Dean of the School of Information Technologies at TalTech. Gert shares how Estonia is preparing to teach artificial intelligence in high schools and why the country’s new AI-focused bachelor’s program is critical for shaping future innovators. We also hear from…

1
[Solutions Spotlight] Hydrogenation: Bridging the gap between nitration and phosgenation 18:15

20d ago18:15

18:15

Hydrogenation can serve as a critical link in chemical synthesis, particularly between nitration and phosgenation. When integrated strategically, it helps enable safer, more efficient production processes. To better understand this connection, we spoke with Dr. Luca Mantilli, R&D Chemist at Valsynthese, the fine chemicals division of Société Suisse…

1
Donna Cryer: Advocacy, Drug Incentives & Research Crisis 49:05

20d ago49:05

49:05

In this episode of the Vital Health Podcast, host Duane Schulthess sits down with patient advocate and Global Liver Institute founder Donna Cryer. They trace her journey from Harvard and the DOJ prosecutor’s office to becoming a liver transplant recipient and a leading voice in healthcare policy. Donna shares insights on orphan drug incentives, the…

1
A cure worse than the disease? Using tariffs to bolster U.S. pharma manufacturing 27:54

23d ago27:54

27:54

In this episode of Talking the Cure, Phil Katz talks with Cybil Roehrenbeck, Josh Gelula, and Kelly Zhang about the announced and seemingly ever-changing plans for tariffs on imported goods – and pharmaceutical products in particular – may effect the industry, as well as the availability and cost of drugs. The discussion unpacks the law, the politi…

1
VT’s Grumpies Talk IRA with Virginia Acha 58:34

25d ago58:34

58:34

In this special Grumpies episode, host Duane Schulthess, CEO of Vital Transformation, is joined by neuroscientist and US Business Director Joe Hammang, consulting economist Dr. Harry Bowen, and MSD Associate VP of Science and Regulatory Policy Virginia “Ginny” Acha. They examine the IRA and question its promise to lower drug prices for Medicare ben…

1
Daniela Marino, CUTISS 🇨🇭 | Skin Tissue Therapeutics, TechBio | E33 [Sponsored] 1:06:13

27d ago1:06:13

1:06:13

We’re online with Daniela Marino, CEO and co-founder of one of the best companies in Europe for tissue therapeutics, CUTISS.We discussed the story behind CUTISS and its current series C fundraising. We also discussed cell therapy in general and why kids are good at preventing burnout.---This episode is sponsored by CUTISS, the only TechBio company …

1
Tariffs, Trade Turbulence & Customs Insights ft. Lars Karlsson 42:48

1M ago42:48

42:48

In Episode 78 of Trade Splaining, hosts Rob and Ardi explore the complex impact of tariffs on global trade, the humorous yet insightful nature of episode 78, and unique trade issues around the world. Guest Lars Karlsson from Maersk discusses how both small and large companies are navigating the new trade realities. The episode also covers topical i…

1
Editor’s (re)View: BMS, Merck, Roche see manufacturing flexibility as key to dealing with tariffs 4:26

1M ago4:26

4:26

The three Big Pharma companies on their earnings calls this week tried to reassure investors that they have the global footprints to mitigate the effects of tariffs.By Pharma Manufacturing

1
Steve Usdin: Tariffs, Price Controls, & Inflation Reduction Act (IRA) 56:35

1M ago56:35

56:35

In this episode, host Duane Schulthess sits down with Steve Usdin, Senior Washington Editor at BioCentury Publications since 1993 and one of the most cited experts on FDA regulation, Medicare policy and the political forces driving biopharma innovation, to explore the major forces reshaping U.S. life sciences: looming Section 232 tariff probes, the…

1
Joris Pezzini, Alira Health | Hottest Biotech Insights | E32 [Sponsored] 1:10:41

1M ago1:10:41

1:10:41

We’re in Barcelona 🇪🇸 with Joris Pezzini from Alira Health to discuss the hottest biotech insights right now, including obesity, I&I, radiopharmaceuticals and ADCs.---This episode is sponsored by Alira Health, an advisor and clinical development partner for life sciences companies. Learn more at https://bit.ly/alirahealth-flotbio-1---⭐️ ABOUT THE S…

1
AI, e-governance, and the future of digital transformation 1:00:05

1M ago1:00:05

1:00:05

We dive into Estonia's e-governance journey with insights from Joel Burke, AI policy expert and author of Rebooting A Nation. Joel shares his experience of Estonia's rise as a global leader in digital governance, highlighting the cultural mindset and political courage that helped shape the nation's innovative e-government systems. We also explore h…

1
Thermo Fisher opens cell therapy center, FDA cites Aurobindo site, Trump probes pharma imports ahead of tariffs [The good, the bad, the ugly] 4:13

1M ago4:13

4:13

The good — Thermo Fisher opens center to boost cell therapy development The bad — FDA cites Aurobindo plant after Raleigh inspection The ugly — Trump probes pharma imports as tariff threat loomsBy Pharma Manufacturing

1
Christophe Bourdon, LEO Pharma 🇩🇰 | Biopharma Turnaround | E31 50:47

2M ago50:47

50:47

We’re in Copenhagen 🇩🇰 with Christophe Bourdon, the CEO who turned a 116-year-old biopharma company from the brink of failure to success.We discuss the lessons behind the turnaround, innovation in dermatology, especially biologicals and I&I, and living in eight different countries.⭐️ ABOUT THE SPEAKERChristophe Bourdon came to be CEO of LEO Pharma …

1
Novartis to invest $23B in US sites, US urged to invest $15B in biotech counter to China, Trump warns of major pharma tariffs [The good, the bad, the ugly] 4:10

2M ago4:10

4:10

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad, and one ugly. Up this week: The good — Novartis to invest $23B in U.S. manufacturing and R&D, including seven new sites The bad — U.S. urged to invest $15B to counter China’s biotech rise The ugly — Trump signals ‘major’ tariffs on pharm…

1
China’s China Shock & Tariff Reality Check ft. Peter S. Goodman 36:51

2M ago36:51

36:51

Episode 77: China’s China Shock & Tariff Reality Check ft. Peter S. Goodman Episode Summary: In Episode 77 of Trade Splaining, we dig into China’s very own “China Shock,” why Budweiser is going budget in Shanghai, and how the global economy might be looking a lot more like... China’s. Plus, New York Times journalist Peter S. Goodman returns for his…

1
Christoph Broja, EQT 🇩🇪🇳🇱 | #1 European Biotech VC, LSP Marriage, ADCs | E30 1:02:10

2M ago1:02:10

1:02:10

We’re in Munich 🇩🇪 with Cristoph Broja, Partner at EQT Life Sciences, the top venture capital firm in Europe.We talk about his lessons up until becoming a partner at the firm. We also talk about how to invest in hot areas such as obesity or ADCs, and the importance of being curious. ⭐️ ABOUT THE SPEAKERCristoph Broja has been a Partner at EQT Life …

1
Cellares, Cabaletta validate automated CAR T production, FDA warns Aspen over sterility issues, rejects Hengrui, Elevar cancer combo again [The good, the bad, the ugly] 3:18

2M ago3:18

3:18

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad, and one ugly. Up this week: The good — Cellares, Cabaletta validate automated CAR T production The bad — FDA warns Aspen over sterility issues The ugly — FDA rejects Hengrui, Elevar cancer combo again…

1
From Huaweigate to the AI Act: how to bake bias in 25:59

2M ago25:59

25:59

Last week, Brussels went reeling under another corruption scandal! This time it's Chinese big tech giant Huawei whose offices just behind the European Parliament have been raided - along with those of 15 former and current MEPs from the EPP and S&D groups. Huawei is, according to the Belgian prosecutors, being investigated for ”active corruption wi…

1
The Green Transition, Customs Fraud & Why Tariffs Might Save the WTO (sort of) 38:42

2M ago38:42

38:42

Episode Summary: In this episode of Trade Splaining, we unpack the latest twists in the Green Transition—spoiler alert: China’s winning. We also explore how chaos is reshaping global trade, why Manchester United’s new stadium might cost a fortune (hint: tariffs), and the Swiss government's crackdown on... cheap meat? Our guest, Professor Joost Pauw…

1
Philipp Baaske, NanoTemper 🇩🇪 | Bootstrapping in Biotech | E29 [Sponsored] 1:11:11

2M ago1:11:11

1:11:11

We’re in Munich with Philipp Baaske, one of the best life science tools founder in Europe. We talked about the lessons building this life science tools business specialized in protein interactions. We also talked about the difficulty and rewards of entrepreneurship, and the impact of life science tools. ___ This episode is sponsored by NanoTemper T…

1
The cyber security challenge: protecting nations and industries 54:05

2M ago54:05

54:05

This time, we explore the critical role of cyber security in an increasingly digital world. Our hosts, Johanna-Kadri Kuusk and Petra Holm, talk with two experts to explore the challenges and solutions associated with combining digital transformation and security. In this episode: Nick Washer, the Global Head of Defence of Nortal, discussed: The rol…

1
Axplora expands ADC capacity, Merck KGaA CDMO business slump, FDA issues a warning letter to Granules India [The good, the bad, the ugly] 3:44

3M ago3:44

3:44

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad, and one ugly. Up this week: The good — Axplora expands its antibody-drug conjugate (ADC) manufacturing capacity to support growing demand. The bad — Merck KGaA’s CDMO business reports a decline The ugly — The FDA issues a warning letter …

1
EIB in focus: Rethinking Europe's financial future with Yanis Varoufakis 33:42

3M ago33:42

33:42

The EU’s financial system operates in the shadows, with institutions like the European Investment Bank (EIB) wielding immense financial power, but who actually benefits? In the latest episode of EU Watchdog Radio, we sit down with Yanis Varoufakis - former Greek Finance Minister, Member of the Greek Parliament, and relentless critic of financial el…

1
Eli Lilly expands manufacturing to boost supply, FDA blocks imports from two Indian API makers, ICU Medical recalls potassium chloride injection bags over labeling error [The good, the bad, the ugly] 3:54

3M ago3:54

3:54

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad, and one ugly. Up this week: The good — Eli Lilly expands manufacturing to boost supply The bad — FDA blocks imports from two Indian API makers over manufacturing violations The ugly — ICU Medical recalls potassium chloride injection bags…

1
Mathias Uhlen 🇸🇪 | Entrepreneurial Scientist, 26 times | E28 49:25

3M ago49:25

49:25

We’re online 🇸🇪 with Mathias Uhlen, one of the best entrepreneurial scientists in Europe. We talked about the entrepreneurial mindset in academia. We also talked about AI for biology and why he doesn’t believe in the current anti-ageing drugs. ⭐️ ABOUT THE SPEAKER Looking at the career of Mathias Uhlen can only leave you feeling impressed. He has c…

1
The Trade War Heats Up, China’s Biotech Rise & Switzerland’s Beaver Problem 29:53

3M ago29:53

29:53

Episode 75: Tariffs, Work From Home & Beaver Hunting? Episode Summary: In this episode of Tradesplaining, Rob and Ardi tackle tariffs, Gen Z’s middle management crisis, and the work-from-home debate. As Trump’s economic policies continue reshaping global trade, we look at the real-world impact of escalating tariffs, Canada and Mexico’s shifting str…

1
Expanding Oncology Treatments: PRIME-ROSE and the Future of Drug Repurposing 26:55

3M ago26:55

26:55

In this episode of the Vital Health Podcast, host Duane Schulthess speaks with two key voices driving the PRIME-ROSE initiative: Gro Live Fagereng, Project Manager of the EU-project PRIME-ROSE and Coordinator of Precision Cancer Medicine at Oslo University Hospital, and Henk van der Pol, Ph.D. Candidate at Leiden University Medical Center. They exp…

1
Novartis boosts Slovenia investment to $3.6B, Trump tariffs could unsettle biopharma FDI, FDA warns Global Calcium, blocks US imports [The good, the bad, the ugly] 4:24

3M ago4:24

4:24

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Novartis boosts Slovenia investment to $3.6B The bad — Trump tariffs unsettle biopharma FDI The ugly — FDA warns Global Calcium, blocks US importsBy Pharma Manufacturing

1
Estonia's e-ID journey and the rise of the EU Digital Identity Wallet 1:00:25

3M ago1:00:25

1:00:25

We delve into the intriguing world of electronic identification, exploring its evolution and impact from local and global perspectives. Join our hosts, Petra Holm and Johanna-Kadri Kuusk, as they guide you through Estonia's groundbreaking e-ID initiatives in the 90s to the exciting prospects of the EU digital wallet. In this episode: Kalev Pihl, CE…

1
Tomato Tariffs, AI's Sputnik Moment and Taliban Tourism 45:32

4M ago45:32

45:32

Episode Summary: In this episode of Trade Splaining, hosts Rob and Ardi dive into the latest on tariffs, AI disruptions, and surprising tourism trends. We break down the new wave of tariffs, their impact on global trade, and what they signal for U.S. economic strategy. Plus, we explore China’s DeepSeek AI breakthrough, the EU’s struggle to stay com…

1
Thomas Ybert, DNA Script 🇫🇷 | DNA Printing & Synthesis | E27 58:36

4M ago58:36

58:36

We’re online 🇫🇷 with Thomas Ybert, the co-founder of DNA Script, the leading biotech for DNA printing of oligos. We talked about the commercialization of the first DNA printer. We also talked about company building at large and how to expand to the US successfully. ⭐️ ABOUT THE SPEAKER At just 30 years old, Thomas Ybert co-founded DNA Script in 201…

1
Estonia: 100% digital and 0% bureaucrazy 1:01:44

4M ago1:01:44

1:01:44

Join us in celebrating Estonia's remarkable achievement of full digitalization of all public services, including divorce, marking a new era of 0% bureaucracy. This episode features discussions with influential leaders like Priit Kongo, Siim Sikkut, and Luukas Ilves, who share insights on the digital transformation that has positioned Estonia as a g…

1
2025 Predictions Episode 22:24

4M ago22:24

22:24

Welcome to Trade Splaining, the podcast that makes sense of international trade, business, and expat life without putting you to sleep! In our first episode of 2025, Rob and Ardi dive into a new year of trade predictions, global trends, and some surprising insights about life, business, and...sausages? In This Episode: 2025 Trade Predictions: What’…

1
The corporate fight against PFAS restriction 30:20

5M ago30:20

30:20

What does a lipstick, a non-stick frying pan and Scotchgard have in common? They all contain PFAS, a.k.a., forever chemicals! In this episode, Vicky Cann, campaigner and researcher at CEO, explains how her huge report "Chemical reaction - Inside the corporate fight against the EU’s PFAS restriction" came to be and what were the most shocking result…

1
FDA approves Opdivo subcutaneous version, Marinus Pharmaceuticals sells operations, Novo Nordisk pushes back against compounding pharmacies [The good, the bad, the ugly] 3:19

5M ago3:19

3:19

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Opdivo subcutaneous version The bad — Marinus Pharmaceuticals sells operations The ugly — Novo Nordisk pushes back against compounding pharmacies…

1
Predicting Economic Trends, Indigenous Art, and the Revival of Mercantilism 45:11

5M ago45:11

45:11

Episode 72: Predicting Economic Trends, Indigenous Art, and the Revival of Mercantilism In this week’s episode of Trade Splaining, Rob and Ardian explore the latest quirks and complexities of global trade and economics, with a special focus on cultural preservation. 🎙️ What You’ll Hear: 💄 Lipstick Economics: How luxury consumer trends hint at econo…

1
Meet the Big Meat Lobby 37:01

5M ago37:01

37:01

In this last episode of EU watchdog radio of 2024 we dive into the topic of the global power of the Big Meat lobby and how two dozen ultra rich companies dominate the political and policy agenda including at the FAO. We talk to professor Paul Behrens, climate expert at Oxford university and Caitlin Smith, senior campaigner at Changing Markets Found…

1
Breaking Barriers: The Prime Rose Project and Off-Label Drug Innovations 29:15

5M ago29:15

29:15

Join host Duane Schulthess on the Vital Health Podcast as he explores the groundbreaking Prime Rose Project, an initiative redefining the use of off-label drugs in oncology. Featuring insights from Dr. Hans Gelderblom, Chair of Medical Oncology at Leiden University Medical Center, and Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, a member of t…

1
Straight to business: from e-Residency to real-time economy 43:19

6M ago43:19

43:19

This time we uncover how Estonia, the world's leading digital society, is transforming government and business operations through innovative technologies. In this episode, we dive deep into the concept of the real-time economy—a game-changing initiative that Estonia is leading to reduce the administrative burdens on entrepreneurs and enable more im…

1
EU approves Novo-Catalent acquisition, CDMO National Resilience announces layoffs, FDA investigates blood cancer reports in gene therapy patients [The good, the bad, the ugly] 2:58

6M ago2:58

2:58

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — EU approves Novo-Catalent acquisition The bad — CDMO National Resilience announces layoffs The ugly — FDA investigates blood cancer reports in gene therapy patients…

1
Impact of the Inflation Reduction Act on Venture Capital in Life Sciences 36:11

6M ago36:11

36:11

In this Vital Health Podcast, John Stanford, Executive Director of Incubate, discusses the impact of the Inflation Reduction Act (IRA) on venture capital investments in life sciences. Stanford emphasizes that the IRA's price control mechanisms have led to significant shifts in funding, particularly away from small-molecule drug development, creatin…

1
FDA approves Imkeldi oral solution, Alector axes workforce, Novartis announcnes layoffs [The good, the bad, the ugly] 3:12

6M ago3:12

3:12

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Imkeldi oral solution The bad — Alector axes workforce The ugly — Novartis announcnes layoffsBy Pharma Manufacturing

1
Gunilla Osswald, BioArctic 🇸🇪 | Leqembi, Alzheimer’s disease | E26 54:25

6M ago54:25

54:25

We’re at BIO-Europe in Stockholm 🇸🇪 with Gunilla Osswalld, the CEO of BioArctic, the inventor of one of the only drugs that have worked for Alzheimer's. We talked about the science and business behind Leqembi. We also talked about the Alzheimer’s field at large and transitioning from big pharma to biotech. — — — Thank you to today’s sponsor, Turbin…

1
Tarantulas, Tariffs, and Trade Wars: Ambassador Maria Pagan on Global Trade’s Future 44:34

6M ago44:34

44:34

Episode 71: Tarantulas, Tariffs, and Trade Wars: Ambassador Maria Pagan on Global Trade’s Future In this week’s episode of Tradesplaining, Rob and Ardi tackle the unexpected, the essential, and the downright quirky in global trade and policy. Joined by Ambassador Maria Pagan, U.S. representative to the WTO, this episode offers insights and plenty o…

1
Sean Marett 🇩🇪 | BioNTech, Art of Dealmaking | E25 1:14:55

6M ago1:14:55

1:14:55

We’re in Hamburg with Sean Marett, who has been instrumental to the success of BioNTech for 12 years. We talked about the secrets behind BioNTech’s success. We also talked about the art of dealmaking and working with China. ⭐️ ABOUT THE SPEAKER Sean joined BioNTech in 2012 as part of the Management Board. He was instrumental in the growth of the co…

1
FDA grants Regenxbio accelerated path for Duchenne, Neurogene reports death in Rett trial, Halozyme drops Evotec bid [The good, the bad, the ugly] 3:19

6M ago3:19

3:19

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA grants Regenxbio accelerated approval pathway for Duchenne gene therapy The bad — Neurogene reports patient death in Rett syndrome gene therapy trial The ugly — Halozyme withdraws acquisition pro…

Podcasts Worth a Listen

EU Biotech Podcasts

Podcasts Worth a Listen

Quick Reference Guide